{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:33:19Z","timestamp":1780918399372,"version":"3.54.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/13543776.2021.1902990","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T16:03:59Z","timestamp":1615565039000},"page":"759-772","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":45,"title":["Synthetic molecules as DprE1 inhibitors: A patent review"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd.","family":"Imran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-3848","authenticated-orcid":false,"given":"Alshrari","family":"A.S.","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Faculty of Science, Northern Border University, Arar, Saudi Arabia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdy Kh.","family":"Thabet","sequence":"additional","affiliation":[{"name":"cDepartment of Chemistry, Faculty of Arts and Science, Northern Border University, Rafha, Saudi Arabia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-461X","authenticated-orcid":false,"family":"Abida","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-0457","authenticated-orcid":false,"given":"Md.","family":"Afroz Bakht","sequence":"additional","affiliation":[{"name":"dDepartment of Chemistry, College of Science and Humanities, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2020.02.005"},{"key":"cit0002","unstructured":"World Health Organization. Global tuberculosis report. 2019. Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/en\/ (Accessed on September 15, 2020)."},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8070979"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneumo.2014.09.001"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/1753465813503028"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.09.004"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2017.03.002"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01207-9"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37562016000000388"},{"key":"cit0010","unstructured":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment [Internet]. Geneva: World Health Organization; 2020. PMID: 32603040."},{"key":"cit0011","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. PMID: 30946559."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/jam.14478"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.03.020"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.10.004"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.03.007"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-013-5218-x"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1021\/ja106357w"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171583"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.04.026"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-012-4013-4"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.2174\/138161282027140630122724"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-018-0441-2"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3390\/app10072269"},{"issue":"3","key":"cit0024","first-page":"61","volume":"92","author":"Mariandyshev AO","year":"2020","journal-title":"Ter Arkh"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02020-19"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2020.107718"},{"key":"cit0027","unstructured":"Lluis BP, inventor; Glaxosmithkline intellectual property development limited, assignee. antituberculosis agent. United States Patent US 10624893 B2. 2020, April 21."},{"key":"cit0028","unstructured":"Carlos AG, inventor; Glaxosmithkline intellectual property development limited, assignee. novel tetrazole compounds and their use in the treatment of tuberculosis. United States Patent Application Publication US 20200231555 A1. 2020, July 23."},{"key":"cit0029","unstructured":"Esther PDF, inventor; GlaxoSmithKline intellectual property development limited, assignee. novel compounds. United States Patent Application Publication US20200170997A1. 2020, June 4."},{"key":"cit0030","unstructured":"Esther PDF, inventor; GlaxoSmithKline intellectual property development limited, assignee. novel compounds. United States Patent Application Publication US20200253967A1. 2020, August 13."},{"key":"cit0031","unstructured":"David BA, inventor; GlaxoSmithKline intellectual property development limited, assignee. sanfetrinem or a salt or ester thereof for use in treating Mycobacterial infection. United States Patent Application Publication US20200289462A1. 2020. September 17."},{"key":"cit0032","unstructured":"Esther PDF, inventor; GlaxoSmithKline intellectual property development limited, assignee. novel compounds. International Publication Number WO2019034700A1. 2019, February 21."},{"key":"cit0033","unstructured":"Carlos AG, inventor; GlaxoSmithKline intellectual property development limited, assignee. novel tetrazole compounds and their use in the treatment of tuberculosis. International Publication Number WO2019034729A1. 2019, February 21."},{"key":"cit0034","unstructured":"Florian K, inventor; leibniz-institu fur naturstoff-forschung und infektionsbiologie E.V. Hans-Knoell institut, assignee. new antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism. International Publication Number WO2018055048A1. 2018, March 29."},{"key":"cit0035","unstructured":"Yoshikazu H, inventor; Otsuka pharmaceutical company limited, assignee. pharmaceutical composition. Japanese Patent Application Publication JP2017141224A. 2017, August 17."},{"key":"cit0036","unstructured":"Makarov AV, inventor; Alere International, assignee. Benzothiazinone derivatives and their use as antibacterial agents. United States Patent US7863268B2. 2011, January 4."},{"key":"cit0037","unstructured":"Shimizu H, inventor; Otsuka Pharmaceutical Co., Ltd., assignee. heterobicyclic compounds and their use for the treatment of tuberculosis. United States Patent US10053446B2. 2018, August 21."},{"key":"cit0038","unstructured":"Shimizu H, inventor; Otsuka Pharmaceutical Co., Ltd., assignee. heterobicyclic compounds and their use for the treatment of tuberculosis. United States Patent US10464926B2. 2019, November 5."},{"key":"cit0039","unstructured":"Shirude PS, inventor; global alliance for TB drug development, assignee. azaindole compounds, synthesis thereof, and methods of using the same. United States Patent US9163020B2. 2015, October 20."},{"key":"cit0040","unstructured":"Makarov V, inventor; ecole polytechnique federale de lausanne, assignee. 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections. United States Patent US8796264B2. 2014, August 5."},{"key":"cit0041","unstructured":"Changlun A, inventor; Qingdao Jiao pharmaceutical technology company limited, assignee. azaindole amide compounds and preparation method and application thereof. Chinese Patent Application Publication CN111393435A. 2020, July 10."},{"key":"cit0042","unstructured":"Chunhua Q, inventor; Soochow University, assignee. Benzothiazinone derivatives, preparation method thereof, and application as antituberculosis drugs. Chinese Patent Application Publication CN111303075A. 2020, June 19."},{"key":"cit0043","unstructured":"Chunhua Q, inventor; Soochow University, assignee. Benzothiazinone compound, preparation method thereof, and application as antituberculosis medicine. Chinese Patent Application Publication CN111269197A. 2020, June 12."},{"key":"cit0044","unstructured":"Haihong H, inventor; institute of materia medica, Chinese academy of medical sciences, assignee. 2-arylamino-substituted thienylimide ester compound and preparation method and application thereof. Chinese Patent Application Publication CN110759889A. 2020, February 7."},{"key":"cit0045","unstructured":"Desai R, inventor; Cadila healthcare limited, assignee. Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria. International Publication Number WO2019239382A1. 2019, December 19."},{"key":"cit0046","unstructured":"Huiyuan G, inventor; institute of medicinal biotechnology, Chinese academy of medical sciences, assignee. diazospiro fragment-containing imidazo[1,2-alpha]pyridine-3-amide compound and preparation method and application thereof. Chinese Patent Application Publication CN109503631A. 2019, March 22."},{"key":"cit0047","unstructured":"Jie C, inventor; Wuhan Huajie century biopharmaceutical company limited, assignee. DprE1 enzyme inhibitor. Chinese Patent Application Publication CN108623527A. 2018, October 9."},{"key":"cit0048","unstructured":"Lin D, inventor; Chengdu Normal University, assignee. Nitrofuran antituberculous component. Chinese Patent Application Publication CN108558858A. 2018, September 21."},{"key":"cit0049","unstructured":"Chao G, inventor; Sichuan University, assignee. Benzothiazine derivative, a preparation method, and uses thereof. Chinese Patent Application Publication CN108456204A. 2018, August 28."},{"key":"cit0050","unstructured":"Nikolaevich CV, inventor; FGBUN Institut Organicheskogo Sinteza im. I. Ya. Postovskogo Uralskogo Otdeleniya RAN, assignee. 5-Fluoro-2-(4-ethoxycarbonyldipiperazine-1-yl)-1,3-benzothiazine-4-one, which has anti-tuberculosis activity. Russian Patent RU2663848C1. 2018, August 10."},{"key":"cit0051","unstructured":"Florian K, inventor; Leibniz-Institu fur naturstoff-forschung und infektionsbiologie E.V. Hans-Knoell Institut, assignee. new antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism. European Patent Application Publication EP3515920A1. 2019, July 31."},{"key":"cit0052","unstructured":"Borisovna BO Inventor; FED Gosudarstvennoe Unitarnoe Predpriyatie Gosudarstvennyj Ordena Trudovogo Krasnogo Znameni Nauchno, assignee. Quaternary ammonium derivatives of 2-aminothiophen-3-carboxylates having antituberculosis activity. Russian Patent RU2629369C1. 2017, August 29."},{"key":"cit0053","unstructured":"Miller MJ, inventor; University of Notre Dame DU LAC, assignee. 1,3-Benzothiazinone, sulfoxide, and sulfone compounds with electrophilic substituent. United States Patent US9708339B2. 2017, Jul 18."},{"key":"cit0054","unstructured":"Miller MJ, inventor; University of Notre Dame DU LAC, assignee. 1,3-benzothiazinone sulfoxide and sulfone compounds. United States Patent US9481683B2. 2016, November 1."},{"key":"cit0055","unstructured":"Chatterjee AK, inventor; the California institute for biomedical research, assignee. compounds for treatment of drug-resistant and persistent tuberculosis. United States Patent Application Publication US20160194299A1. 2016, July 7, 2016."},{"key":"cit0056","unstructured":"Yuquan W, inventor; Sichuan university, assignee. benzothiazine-thione derivatives, preparation method thereof and purpose thereof. Chinese Patent CN102276598B. 2014, November 5."},{"key":"cit0057","unstructured":"Yulevich LA, inventor; FED gosudarstvennoe uchrezhdenie fed issledovatelskij tsentr fundamentalnye osnovy biotekhnologii, assignee. Pyranoindoles with antituberculosis activity. Russian Patent RU2675240C1. 2018, December 18."},{"key":"cit0058","unstructured":"Shirude PS, inventor; foundation for neglected disease research, assignee. benzimidazoles derivatives as antituberculosis agents. International Publication Number WO2020188405A1. 2020, September 24."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.3390\/app10165704"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.09.025"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.3390\/app10020623"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1902990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T18:32:50Z","timestamp":1627324370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1902990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/13543776.2021.1902990"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1902990","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}